Please use this identifier to cite or link to this item: http://hdl.handle.net/1822/66395

TitleTumor-targeting polycaprolactone nanoparticles with codelivery of paclitaxel and IR780 for combinational therapy of drug-resistant ovarian cancer
Author(s)Pan, Q.
Tian, J.
Zhu, H.
Mao, Z.
Oliveira, Joaquim M.
Reis, R. L.
Xiao, L.
KeywordsCancer therapy
PCL nanoparticles
Tumor
LHRH peptide
combinational cancer therapy
tumor targeting
drug-resistant ovarian cancer
Issue dateMar-2020
PublisherACS Publications
JournalACS Biomaterials Science and Engineering
CitationPan Q., Tian J., Zhu H., Mao Z., Oliveira J. M., Reis R. L., Xiao L. Tumor-Targeting Polycaprolactone Nanoparticles with Codelivery of Paclitaxel and IR780 for Combinational Therapy of Drug-Resistant Ovarian Cancer, ACS Biomaterials Science and Engineering, Vol. 6, Issue 4, pp. 2175-2185, doi:10.1021/acsbiomaterials.0c00163, 2020
Abstract(s)Synergetic treatments that combine chemotherapy with photothermal/photodynamic therapy have been developed as promising new strategies for cancer therapy, especially for drug-resistant cancers. To achieve optimized synergetic outcomes for cancer therapy, it is highly desirable to selectively and simultaneously deliver both chemotherapeutics and near-infrared photosensitizers to the cancer tissues and cells, enhancing local accumulation. Here we report the preparation of poly-ε-caprolactone nanoparticles (PCL NPs) using bovine albumin as a stabilizer; the nanoparticles are loaded with IR780 and paclitaxel (PTX) for combinational phototherapy and chemotherapy. Moreover, in order to enable active targeting toward ovarian cancer, a specific peptide recognizing luteinizing hormone-releasing hormone receptors (LHRH) on ovarian cancer cells was covalently grafted onto the surface of the as-prepared NPs. As a result, LHRH peptide modified PCL (PCL-LHRH) NPs demonstrated increased internalization in ovarian tumor cells in vitro and selective targeting in tumor xenografts in vivo. PTX and IR780 can be efficiently encapsulated into PCL-LHRH NPs by an oil-in-water emulsion and solvent evaporation method. The systematic administration of ovarian tumor targeting PCL-LHRH/IR780-PTX can efficiently hinder the growth of drug-resistant xenografts in vivo with the assistance of an 808 nm near-infrared laser. These findings indicate that peptide mediated tumor targeting multifunctional nanomaterials may have remarkable profits in controlled drug delivery and synergistic therapy on drug-resistant cancer.
TypeArticle
URIhttp://hdl.handle.net/1822/66395
DOI10.1021/acsbiomaterials.0c00163
ISSN2373-9878
Publisher versionhttps://pubs.acs.org/doi/abs/10.1021/acsbiomaterials.0c00163
Peer-Reviewedyes
AccessRestricted access (UMinho)
Appears in Collections:3B’s - Artigos em revistas/Papers in scientific journals

Files in This Item:
File Description SizeFormat 
20274-20 ACSBSE Li Xiao.pdf
  Restricted access
924,76 kBAdobe PDFView/Open

Partilhe no FacebookPartilhe no TwitterPartilhe no DeliciousPartilhe no LinkedInPartilhe no DiggAdicionar ao Google BookmarksPartilhe no MySpacePartilhe no Orkut
Exporte no formato BibTex mendeley Exporte no formato Endnote Adicione ao seu ORCID